FDA cited Seaway Pharma for manufacturing-quality rule violations in OTC oral liquid drugs, including release and component-testing failures.
What happened
FDA inspected the Massena, NY drug manufacturing facility from May 19 to June 18, 2025. It found violations of Current Good Manufacturing Practice (CGMP), the rules for drug manufacturing, including that the quality unit (the group that approves batch release) released numerous OTC oral liquid batches before reviewing all test results. FDA also found that high-risk glycerin and sorbitol were used and distributed before identity testing for diethylene glycol (DEG) or ethylene glycol (EG), and that process validation was inadequate.
What FDA found
The quality unit (the group that approves batch release) failed to follow its written release procedure and released many batches before all test results were reviewed.
21 CFR 211.22(d)The quality unit failed to ensure each batch was tested for active ingredient strength before release.
21 CFR 211.165(a)Laboratory records did not include complete data from all tests needed to show compliance with specifications.
21 CFR 211.194(a)The firm used and distributed OTC oral liquids made with glycerin and sorbitol before testing these high-risk components for identity, including DEG/EG.
21 CFR 211.84(d)(1)The firm lacked adequate process validation for OTC products, including infant and child products, and validation records were incomplete.
21 CFR 211.100(a)
What FDA wants
FDA tells the company to reply in writing within 15 working days with what it has done and how it will prevent recurrence, and to provide the requested assessments, commitments, and corrective-action timeline. If it cannot finish, it must give reasons and a schedule.
Who should pay attention
- brands that use Seaway Pharma as a contract manufacturer
- companies selling OTC oral liquids for infants and children
- drug makers using glycerin or sorbitol in oral liquids
This is a summary. Read the original letter on fda.gov.